

*Agenda:* Break.

*Place:* National Institute on Aging, Biomedical Research Center, 251 Bayview Blvd., Baltimore, MD 21224 (Hybrid).

*Closed:* May 31, 2024, 11:45 a.m. to 1:00 p.m.

*Agenda:* To review and evaluate executive Session Luncheon.

*Place:* National Institute on Aging, Biomedical Research Center, 3A519/Virtual, 251 Bayview Blvd., Baltimore, MD 21224 (Hybrid).

*Closed:* May 31, 2024, 1:00 p.m. to 1:15 p.m.

*Agenda:* To review and evaluate laboratory/Branch Chief Leadership Overview (Lenore Launer, Ph.D., Laboratory Chief, Senior Investigator, LEPS).

*Place:* National Institute on Aging, Biomedical Research Center, 251 Bayview Blvd., Baltimore, MD 21224 (Hybrid).

*Closed:* May 31, 2024, 1:15 p.m. to 1:30 p.m.

*Agenda:* To review and evaluate discussion with the Laboratory/Branch Chief.

*Place:* National Institute on Aging, Biomedical Research Center, 251 Bayview Blvd., Baltimore, MD 21224 (Hybrid).

*Closed:* May 31, 2024, 1:30 p.m. to 1:45 p.m.

*Agenda:* To review and evaluate leadership Review Discussion.

*Place:* National Institute on Aging, Biomedical Research Center, 251 Bayview Blvd., Baltimore, MD 21224 (Hybrid).

*Closed:* May 31, 2024, 1:45 p.m. to 2:30 p.m.

*Agenda:* To review and evaluate BSC members to meet with Fellows from LEPS.

*Place:* National Institute on Aging, Biomedical Research Center, 251 Bayview Blvd., Baltimore, MD 21224 (Hybrid).

*Open:* May 31, 2024, 2:30 p.m. to 2:45 p.m.

*Agenda:* Break.

*Place:* National Institute on Aging, Biomedical Research Center, 251 Bayview Blvd., Baltimore, MD 21224 (Hybrid).

*Open:* May 31, 2024, 2:45 p.m. to 3:00 p.m.

*Agenda:* Whole-genome sequencing in non-Alzheimer dementias: Progress, opportunities, and request for cloud resources (Concept) (Bryan J. Traynor, M.D., Ph.D., Senior Investigator, LNG).

*Place:* National Institute on Aging, Biomedical Research Center, 251 Bayview Blvd., Baltimore, MD 21224 (Hybrid).

*Open:* May 31, 2024, 3:00 p.m. to 3:15 p.m.

*Agenda:* Discussion.

*Place:* National Institute on Aging, Biomedical Research Center, 251 Bayview Blvd., Baltimore, MD 21224 (Hybrid).

*Closed:* May 31, 2024, 3:15 p.m. to 4:30 p.m.

*Agenda:* To review and evaluate executive Session (Final discussion of all Principal Investigators reviewed on all days.)

*Place:* National Institute on Aging, Biomedical Research Center, 3C211/Virtual, 251 Bayview Blvd., Baltimore, MD 21224 (Hybrid).

*Closed:* May 31, 2024, 4:30 p.m. to 4:30 p.m.

*Agenda:* To review and evaluate adjourn.

*Place:* National Institute on Aging, Biomedical Research Center, 3C211/Virtual, 251 Bayview Blvd., Baltimore, MD 21224 (Hybrid).

*Contact Person:* Luigi Ferrucci, M.D., Ph.D., Scientific Director, National Institute on Aging, 251 Bayview Boulevard, Suite 100, Room 4C225, Baltimore, MD 21224, 410-558-8110, [LF27Z@NIH.GOV](mailto:LF27Z@NIH.GOV).

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS)

Dated: March 20, 2024.

**Miguelina Perez,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2024-06980 Filed 4-2-24; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Human Genome Research Institute; Notice of Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Council for Human Genome Research, NHGRI.

This is a hybrid meeting held in-person and virtually and is open to the public as indicated below. Individuals who plan to attend in-person or view the virtual meeting and need special assistance or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be videocast and can be accessed from <https://www.genome.gov/event-calendar/102nd-Meeting-of-National-Advisory-Council-for-Human-Genome-Research>.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the intramural programs and projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Advisory Council for Human Genome Research.

*Date:* May 20-21, 2024.

*Closed:* May 20, 2024, 9:00 a.m. to 10:00 a.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Human Genome Research Institute, National Institutes of Health, 6700B Rockledge Drive, Suite 1100, Bethesda, MD 20892 (Hybrid Meeting).

*Open:* May 20, 2024, 10:30 a.m. to 6:00 p.m.

*Agenda:* Report of Institute Director and Institute Staff.

*Place:* National Human Genome Research Institute, National Institutes of Health, 6700B Rockledge Drive, Suite 1100, Bethesda, MD 20892 (Hybrid Meeting).

*Closed:* May 21, 2024, 9:00 a.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Human Genome Research Institute, National Institutes of Health, 6700B Rockledge Drive, Suite 1100, Bethesda, MD 20892 (Hybrid Meeting).

*Contact Person:* Rudy O. Pozzatti, Ph.D., Scientific Review Officer, Scientific Review Branch, National Human Genome Research Institute, 6700B Rockledge Drive, Suite 3100, Rockville, MD 20892, (301) 402-0838, [pozatatr@mail.nih.gov](mailto:pozatatr@mail.nih.gov).

Information is also available on the Institute's/Center's home page: <http://www.genome.gov/council>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS)

Dated: March 29, 2024.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2024-07054 Filed 4-2-24; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HOMELAND SECURITY

### Coast Guard

[Docket No. USCG-2024-0240]

#### National Chemical Transportation Safety Advisory Committee; Vacancies

**AGENCY:** United States Coast Guard, Department of Homeland Security.

**ACTION:** Notice; request for applications.

**SUMMARY:** The U.S. Coast Guard is accepting applications to fill six vacancies on the National Chemical Transportation Safety Advisory Committee (Committee). This Committee advises the Secretary of Homeland Security, via the Commandant of the U.S. Coast Guard on matters relating to the safe and secure marine transportation of hazardous materials.

**DATES:** Completed applications must reach the U.S. Coast Guard on or before June 3, 2024.

**ADDRESSES:** Applications must include: (a) a cover letter expressing interest in an appointment to the National Chemical Transportation Safety Advisory Committee, (b) a resume

detailing the applicant's relevant experience for the position applied for, and (c) a brief biography. Applications should be submitted via email with subject line "NCTSAC Vacancy Application" to *Ethan.T.Beard@uscg.mil*.

**FOR FURTHER INFORMATION CONTACT:**

Lieutenant Ethan Beard, Assistant Designated Federal Officer of the National Chemical Transportation Safety Advisory Committee; telephone 571-607-8905 or email at *Ethan.T.Beard@uscg.mil*.

**SUPPLEMENTARY INFORMATION:** The National Chemical Transportation Safety Advisory Committee is a Federal advisory committee. The National Chemical Transportation Safety Advisory Committee was established by section 601 of the *Frank LoBiondo Coast Guard Authorization Act of 2018* (Pub. L. 115-282, 132 Stat. 4192), and is codified in 46 U.S.C. 15101. The Committee operates under the provisions of the *Federal Advisory Committee Act* (5 U.S.C. ch. 10) and 46 U.S.C. 15109. The Committee provides advice and recommendations to the Secretary of Homeland Security on matters relating to the safe and secure marine transportation of hazardous materials.

The Committee is required to meet at least once a year in accordance with 46 U.S.C. 15109(a)(1). We expect the Committee to meet at least twice a year, but it may meet more frequently. The meetings are generally held in Washington, DC and Houston, Texas.

Under 46 U.S.C. 15109(f)(6)(A), if you are appointed as a member of the Committee, your membership term will expire on December 31st of the third full year after the effective date of your appointment. In accordance with 46 U.S.C. 15109(f)(4), applicants for membership may be required to pass an appropriate security background examination before their appointment to the Committee.

All members serve at their own expense and receive no salary or other compensation from the Federal Government. If you are appointed as member of the Committee, you will be required to sign a Non-Disclosure Agreement and a Gratuitous Services Agreement.

In this solicitation for Committee Members, we will consider applications from members representing the following:

- Chemical manufacturing entities
- Entities related to marine handling or transportation of chemicals
- Marine safety or security entities

- Marine environmental protection entities

The members who will fill the positions described above will be appointed to represent the interest of their respective groups and viewpoints and are not "special Government employees," as defined in 18 U.S.C. 202(a).

In order for the Department to fully leverage broad-ranging experience and education, the National Chemical Transportation Safety Advisory Committee must be diverse with regard to professional and technical expertise. The Department is committed to pursuing opportunities, consistent with applicable law, to compose a committee that reflects the diversity of the Nation's people.

If you are interested in applying to become a member of the Committee, email your application to *Ethan.T.Beard@uscg.mil* as provided in the **ADDRESSES** section of this notice. Applications must include: (a) a cover letter expressing interest in an appointment to the National Chemical Transportation Safety Advisory Committee, (b) a resume detailing the applicant's relevant experience for the position applied for, and (c) a brief biography of the applicant by the deadline in the **DATES** section of this notice.

The U.S. Coast Guard will not consider incomplete or late applications.

**Privacy Act Statement**

*Purpose:* To obtain qualified applicants to fill six vacancies on the National Chemical Transportation Advisory Committee. When you apply for appointment to the National Chemical Transportation Advisory Committee, Department of Homeland Security (DHS) will collect your name, contact information, and any other personal information that you submit in conjunction with your application. DHS will use this information to evaluate your candidacy for Committee membership. If you are chosen to serve as a Committee member, your name will appear in publicly available Committee documents, membership lists, and Committee reports.

*Authorities:* 14 U.S.C. 504; 46 U.S.C. 15101 and 15109; and 18 U.S.C. 202(a), and Department of Homeland Security Delegation No. 00915.

*Routine Uses:* Authorized U.S. Coast Guard personnel will use this information to consider and obtain qualified candidates to serve on the Committee. Any external disclosures of information within this record will be

made in accordance with DHS/ALL-009, Department of Homeland Security Advisory Committee (73 FR 57642, October 3, 2008).

*Consequences of Failure to Provide Information:* Furnishing this information is voluntary. However, failure to furnish the requested information may result in your application not being considered for the Committee.

Dated: March 28, 2024.

**Jeffrey G. Lantz,**

*Director of Commercial Regulations and Standards.*

[FR Doc. 2024-07050 Filed 4-2-24; 8:45 am]

**BILLING CODE 9110-04-P**

**DEPARTMENT OF HOMELAND SECURITY**

**U.S. Customs and Border Protection**

**Notice of Issuance of Final Determination Concerning Omega-3-Acid Ethyl Esters Capsules**

**AGENCY:** U.S. Customs and Border Protection, Department of Homeland Security.

**ACTION:** Notice of final determination.

**SUMMARY:** This document provides notice that U.S. Customs and Border Protection (CBP) has issued a final determination concerning the country of origin of Omega-3-Acid Ethyl Esters Capsules. Based upon the facts presented, CBP has concluded that the Norwegian-origin Omega-3-Acid Ethyl Esters do not undergo a substantial transformation in China when combined with certain inactive ingredients and encapsulated into dosage form.

**DATES:** The final determination was issued on March 28, 2024. A copy of the final determination is attached. Any party-at-interest, as defined in 19 CFR 177.22(d), may seek judicial review of this final determination no later than May 3, 2024.

**FOR FURTHER INFORMATION CONTACT:** Mitchell Emery, Valuation and Special Programs Branch, Regulations and Rulings, Office of Trade, at (202) 325-0321.

**SUPPLEMENTARY INFORMATION:** Notice is hereby given that on March 28, 2024, U.S. Customs and Border Protection (CBP) issued a final determination concerning the country of origin of Omega-3-Acid Ethyl Esters Capsules for purposes of title III of the Trade Agreements Act of 1979. This final determination, Headquarters Ruling (HQ) H331488, was issued at the request of Epic Pharma LLC, under procedures set forth at 19 CFR part 177, subpart B,